Singapore, May 29 -- Japanese startup Precision Medicine Asia (PREMIA) and US-based Lind have announced the formation of Lind Asia, a strategic joint venture dedicated to revolutionising clinical trial enrollment in the Asia-Pacific (APAC) region.

Lind Asia will serve as the exclusive regional partner for Lind's artificial intelligence (AI)-powered screening platform by leveraging PREMIA's deep expertise in managing clinical-genomic databases to accelerate patient eligibility screening for clinical trials. Lind's platform will be localised for healthcare institutions across Taiwan, Japan, South Korea, Singapore and Australia.

Lind Asia's platform has three key pillars:

"We are dedicated to advancing precision medicine across the Asia-P...